@Chris Vertullo. Thanks for your comments. As an orthopaedic surgeon yourself, I can understand why you would have a unique interest in a drug that promises to drastically alter the industry and delay the need for surgery as treatment for OA. To answer your queries one at a time: 1. Recent releases from Paradigm suggests that iPPS treats the underlying pathology of osteoarthritis by reducing inflammation, resolving the bone marrow edema lesions, and down regulating cartilage degrading enzymes. The link you provided is 8 years old, and affirms the drug’s effectiveness as a treatment. 2. Paradigm have patents across the first world for use of PPS in OA treatment. Additionally, Bene Pharma (the global leader in PPS production) have agreed to give sole rights to PAR for production from its facilities. I would suggest that this is as good a moat as one can ask for in the pharmaceutical industry. 3. I suspect that the effectiveness of iPPS treatment would negate the need for an additional anti inflammatory. 4. While opiates are not used in the treatment of OA per say, they are used for pain management. Insomuch as as iPPS reduces pain, comparing it to pain management drugs would be appropriate. If you have technical questions, I’m more than happy to put you in touch with someone who can answer them for you. Feel free to be in touch.

On Paradigm: A company with massive near-term potential -

@Chez Spigelman: Initially we looked at creating a basket of nuclear energy based companies (looking for broad exposure to the theme). We've refined our position since and would be happy to have a conversation if you wanted to give us a call.

On An overlooked commodity with huge catalysts -

@Richard Vivian, you make a fair point. The cost of building a nuclear power station is materially higher than an oil/gas/coal plant. The advantage that nuclear energy has over the long term is that its highly efficient, it has low cost inputs, and its carbon footprint is incomparably smaller than other traditional base load energy sources. I think a simple look at global users of nuclear power is the best measure of value: France generates over 70% of their energy from nuclear, and have done for more than 50 years. Their carbon footprint and electricity bills are among the lowest in the developed world. As battery technology improves we may be able to have a discussion about comparing renewable sources, but we are not there yet. Nor can we know what advances will be discovered to improve traditional energy in the future.

On Like buying oil at $20 a barrel -

@Hew Mills There are not a lot of ways to invest in the space. I'm not aware of many funds that have exposure to uranium at all. If you give me a call I'm happy to discuss how we built exposure in our Fund.

On Like buying oil at $20 a barrel -